Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Jacoline Bromberg, MD, Samar Issa, FRACP, Katerina Bukanina, Monique C Minnema, Tatjana Seute, MD, Marc Durian, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Harry C. Schouten, MD, Wendy B Stevens, MD, Josée Zijlstra, MD, Johanna W. Baars, MD PhD, Marcel Nijland, MD, Kylie Mason, MBBS,PhDFRACP,FRCPA, Aart Beeker, MD, Martin van den Bent, MD, Daphne de Jong, Prof Dr, Michael Anthony Gonzales, BSc, Jeanette K. Doorduijn, MD PhD

Blood (2017) 130 (Supplement 1): 582.

https://doi.org/10.1182/blood.V130.Suppl_1.582.582

Published: 2017

Journal Articles

Teniposide, Cyclophosphamide, and Prednisone in Myeloma after Bortezomib and Imid Failure Is a Useful Option

Kirsty Ann Louise Marshall, MBChB, Henry Siu Him Chan, MBChB, David Simpson, MBChB, FRACP, FRCPA

Blood (2014) 124 (21): 5767.

https://doi.org/10.1182/blood.V124.21.5767.5767

Published: 2014

Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4034.

https://doi.org/10.1182/blood.V120.21.4034.4034

Published: 2012

Journal Articles

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

Blood (2012) 120 (21): 1494.

https://doi.org/10.1182/blood.V120.21.1494.1494

Published: 2012

Journal Articles

Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadephia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation

Blood (2011) 118 (21): 2582.

https://doi.org/10.1182/blood.V118.21.2582.2582

Published: 2011

Journal Articles

Long Term Follow-up of the GELF86 French and Belgian Trials: Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission

E. Bachy, P. Brice, M. Fournier, H. Tilly, C. Haioun, N. Brousse, S. Le Gouil, A. Bosly, B. Coiffier, C. Gisselbrecht, P. Solal-Celigny, G. Salles

Blood (2008) 112 (11): 2590.

https://doi.org/10.1182/blood.V112.11.2590.2590

Published: 2008

Journal Articles

Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia.

Jun Yang, PhD, Alessia Bogni, Ph.D., Cheng Cheng, Ph.D., Wasim K. Bleibel, Jean Cai, Ph.D., Yiping Fan, Ph.D., Wenjian Yang, Ph.D., Jose Claudio Rocha, M.D., Deqing Pei, Wei Liu, M. Eileen Dolan, Ph.D., Ching-Hon Pui, M.D., Mary V. Relling, Pharm.D.

Blood (2007) 110 (11): 1829.

https://doi.org/10.1182/blood.V110.11.1829.1829

Published: 2007

Journal Articles

Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia

Nobuko Hijiya, John C. Panetta, Yinmei Zhou, Emily P. Kyzer, Scott C. Howard, Sima Jeha, Bassem I. Razzouk, Raul C. Ribeiro, Jeffrey E. Rubnitz, Melissa M. Hudson, John T. Sandlund, Ching-Hon Pui, Mary V. Relling

Blood (2006) 108 (13): 3997–4002.

https://doi.org/10.1182/blood-2006-05-024414

Published: 2006

Journal Articles

Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.

Shujie Wang, MD, PhD, Wei Zhang, MD, Wei Lian, MD, Yongji Wu, MD, Nong Zou, MD, Tienan Zhu, MD, Daobin Zhou, MD, Ying Xu, MD, Ti Shen, MD, Yongqiang Zhao, MD, PhD

Blood (2006) 108 (11): 4695.

https://doi.org/10.1182/blood.V108.11.4695.4695

Published: 2006

Journal Articles

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Andrew M. Evens, DO, MS, Jane N. Winter, MD, Nanjiang Hou, MS, Fred Rademaker, PhD, Katalin Kelemen, MD, Beverly Nelson, MD, David Patton, BS, Olga Frankfurt, MD, Stephanie Williams, MD, Seema Singhal, MD, Martin S. Tallman, MD, Steven T. Rosen, MD, Jayesh Mehta, MD, Leo I. Gordon, MD

Blood (2006) 108 (11): 2448.

https://doi.org/10.1182/blood.V108.11.2448.2448

Published: 2006

Journal Articles

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Catherine Sebban, Nicolas Mounier, Nicole Brousse, Coralie Belanger, Pauline Brice, Corinne Haioun, Herve Tilly, Pierre Feugier, Redah Bouabdallah, Chantal Doyen, Gilles Salles, Bertrand Coiffier

Blood (2006) 108 (8): 2540–2544.

https://doi.org/10.1182/blood-2006-03-013193

Published: 2006

Journal Articles

Detection of Proteins Related to Therapeutic Outcome, Including Drug Resistance, in Acute Myeloid Leukemia Using Mass Spectrometry and Gel Based Proteomic Profiling.

Leif Stenke, MD, Lukas Orre, PhD, Sumeer Dhar, PhD, Rolf Larsson, MD, Rolf Lewensohn, MD, Janne Lehtiö, PhD

Blood (2005) 106 (11): 2367.

https://doi.org/10.1182/blood.V106.11.2367.2367

Published: 2005

Journal Articles

Survival Impact of Time Repeated bcl2/IgH Rearrangement Measurements in Follicular Lymphoma Patients Treated with Front-Line Autotransplantation in the GELF-94 Trial by the GELA.

Broussais Florence, Mounier Nicolas, Delfau Marie-Hélène, Cayuela Jean-Marie, MacIntyre Elisabeth, Davi Frederic, Sebban Catherine, Belanger Coralie, Brousse Nicole, Brice Pauline, Haioun Corinne, Tilly Andre, Feugier Pierre, Bosly Andre, Coiffier Bertrand, Salles Gilles

Blood (2005) 106 (11): 981.

https://doi.org/10.1182/blood.V106.11.981.981

Published: 2005

Journal Articles

Treatment of Hematological Malignancies in Central Nervous System with Idarubicin and Teniposide Containing Regimens.

Chun Wang, MD, PhD, Xiaojun He, MD, Qi Cai, MD, Jun Zhu, MD, Haitao Bai, MD

Blood (2005) 106 (11): 4731.

https://doi.org/10.1182/blood.V106.11.4731.4731

Published: 2005

Journal Articles

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

Blood (2005) 105 (10): 3817–3823.

https://doi.org/10.1182/blood-2004-10-3920

Published: 2005

Journal Articles

Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy.

Daniel Rosenblum, MD, Steven Hirschfeld, MD, PhD

Blood (2004) 104 (11): 3128.

https://doi.org/10.1182/blood.V104.11.3128.3128

Published: 2004

Journal Articles

Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.

Auke Beishuizen, MD, PhD, Femke K. Aarsen, MA, Jeanette E.W.M. van Dongen, PhD, MA, Isabelle C. Streng, MA, Rob Pieters, MD, PhD, Karel Hahlen, MD, PhD

Blood (2004) 104 (11): 1955.

https://doi.org/10.1182/blood.V104.11.1955.1955

Published: 2004

Journal Articles

t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS ( GUANOSINE 5′ MONOPHOSPHATE SYNTHETASE ) gene

Linda D. Pegram, Maureen D. Megonigal, Beverly J. Lange, Peter C. Nowell, Janet D. Rowley, Eric F. Rappaport, Carolyn A. Felix

Blood (2000) 96 (13): 4360–4362.

https://doi.org/10.1182/blood.V96.13.4360

Published: 2000

Journal Articles

Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia

Christian M. Zwaan, Gert-Jan L. Kaspers, Rob Pieters, Nicole L. Ramakers-Van Woerden, Monique L. den Boer, Renate Wünsche, Maria M. A. Rottier, Karel Hählen, Elizabeth R. van Wering, Gritta E. Janka-Schaub, Ursula Creutzig, Anjo J. P. Veerman

Blood (2000) 96 (8): 2879–2886.

https://doi.org/10.1182/blood.V96.8.2879

Published: 2000

Journal Articles

Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death

Philip L. Simonian, Didier A.M. Grillot, Gabriel Nuñez

Blood (1997) 90 (3): 1208–1216.

https://doi.org/10.1182/blood.V90.3.1208

Published: 1997

NARROW

Effect of Rituximab in Primary Central Nervous System Lymphoma - results of the Randomized Phase III HOVON 105/ALLG NHL 24 Study

Teniposide, Cyclophosphamide, and Prednisone in Myeloma after Bortezomib and Imid Failure Is a Useful Option

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

Comparison of Short-Term Outcomes Between CSTIBES02 and ALL Ph08 Trials for Young Patients with Philadephia Chromosome-Positive ALL (Ph+ALL) Differing In Imatinib Dose and Amount of Chemotherapy Before Stem Cell Transplantation

Long Term Follow-up of the GELF86 French and Belgian Trials: Complete Remission after First Line Treatment with Conventional Chemotherapy in Newly Diagnosed Follicular Lymphoma Patients Correlates with Prolonged Overall Survival Compared with Partial Remission

Etoposide Sensitivity Does Not Predict MLL Rearrangements or Risk of Therapy-Related Acute Myeloid Leukemia.

Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia

Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

Detection of Proteins Related to Therapeutic Outcome, Including Drug Resistance, in Acute Myeloid Leukemia Using Mass Spectrometry and Gel Based Proteomic Profiling.

Survival Impact of Time Repeated bcl2/IgH Rearrangement Measurements in Follicular Lymphoma Patients Treated with Front-Line Autotransplantation in the GELF-94 Trial by the GELA.

Treatment of Hematological Malignancies in Central Nervous System with Idarubicin and Teniposide Containing Regimens.

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS

Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy.

Outcome of the Rotterdam-84 CNS-ALL Chemotherapy Protocol without Radiotherapy for Isolated Central Nervous System Relapsed Acute Lymphoblastic Leukemia.

t(3;11) translocation in treatment-related acute myeloid leukemia fuses MLL with the GMPS ( GUANOSINE 5′ MONOPHOSPHATE SYNTHETASE ) gene

Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia

Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only